Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Celator's CPX-351 bests standard of care in AML study
August 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

EWING, N.J.—Celator Pharmaceuticals Inc. has released final induction response rate results (complete remission plus complete remission with incomplete hematologic recovery, or CR+CRi) in its Phase 3 study of CPX-351 liposome injection compared with the standard-of-care regimen, or 7+3 (conventional cytarabine and daunorubicin treatment), in patients with untreated high-risk acute myeloid leukemia (AML). Celator partnered with the Leukemia & Lymphoma Society in developing CPX-351. CPX-351 treatment resulted in a relative improvement in induction response rate of 43.2 percent—47.7 percent for CPX-351 vs. 33.3 percent for the 7+3 regimen.
 
Dr. Jeffrey Lancet, senior member and chief of the Leukemia/Myelodysplasia Program at Moffitt Cancer Center and lead investigator on the study, noted, “The results are encouraging because this is the third randomized study in which CPX-351 outperformed the control arm of cytarabine plus an anthracycline in overall response rate.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.